<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04109079</url>
  </required_header>
  <id_info>
    <org_study_id>NIHR 128311</org_study_id>
    <nct_id>NCT04109079</nct_id>
  </id_info>
  <brief_title>Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy</brief_title>
  <acronym>ATNEC</acronym>
  <official_title>ATNEC - Axillary Management in T1-3N1M0 Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases at Presentation After Neoadjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals of Derby and Burton NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospitals of Derby and Burton NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess whether, omitting further axillary treatment (ALND and&#xD;
      ART) for patients with early stage breast cancer and axillary nodal metastases on needle&#xD;
      biopsy, who after NACT have no residual cancer in the lymph nodes on sentinel node biopsy, is&#xD;
      non-inferior to axillary treatment in terms of disease free survival (DFS) and results in&#xD;
      reduced risk of lymphoedema at 5 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: The presence of cancer in the axillary lymph nodes on needle biopsy in patients&#xD;
      with early stage breast cancer before neoadjuvant chemotherapy (NACT) has been the&#xD;
      determinant of the need for axillary treatment (in the form of axillary lymph node dissection&#xD;
      (ALND) or axillary radiotherapy (ART)) after completion of NACT. Treatment to the axilla&#xD;
      damages lymphatic drainage from the arm and patients can subsequently develop lymphoedema,&#xD;
      restricted shoulder movement, pain, numbness, and other sensory problems. As more effective&#xD;
      chemotherapy is now available that results in complete eradication of cancer in the axilla in&#xD;
      around 40 to 70% of patients, extensive axillary treatment might no longer be necessary in&#xD;
      patients with no evidence of residual nodal disease.&#xD;
&#xD;
      Aim: To assess whether, omitting further axillary treatment (ALND and ART) for patients with&#xD;
      early stage breast cancer and axillary nodal metastases on needle biopsy, who after NACT have&#xD;
      no residual cancer in the lymph nodes on sentinel node biopsy, is non-inferior to axillary&#xD;
      treatment in terms of disease free survival (DFS) and results in reduced risk of lymphoedema&#xD;
      at 5 years.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Study design: A pragmatic, phase 3, open, randomised, multicentre trial and embedded economic&#xD;
      evaluation in which participants will be randomised in a 1:1 ratio.&#xD;
&#xD;
      Study population: T1-3N1M0 breast cancer patients aged 18 years or older, with needle biopsy&#xD;
      proven nodal metastases, who after NACT have no residual cancer in the lymph nodes on dual&#xD;
      tracer sentinel node biopsy and removal of at least 3 lymph nodes (sentinel nodes and marked&#xD;
      involved node).&#xD;
&#xD;
      Intervention: All participants will receive human epidermal growth factor receptor 2&#xD;
      (HER2)-targeted treatment, endocrine therapy and radiotherapy to breast or chest wall, if&#xD;
      indicated according to local guidelines. Patients in the intervention group will not receive&#xD;
      further axillary treatment (ALND or ART), whereas those receiving standard care will receive&#xD;
      axillary treatment (ALND or ART) as per local guidelines. Follow-up is annually for at least&#xD;
      5 years.&#xD;
&#xD;
      Outcomes: The co-primary outcomes are disease free survival(DFS) and self-reported&#xD;
      lymphoedema defined as 'yes' to the two questions participants will be asked - 'arm heaviness&#xD;
      during the past year' and 'arm swelling now' from the Lymphoedema and Breast Cancer&#xD;
      Questionnaire at 5 years.&#xD;
&#xD;
      Secondary outcomes: arm function assessed by the QuickDASH (disabilities of the arm, shoulder&#xD;
      and hand) questionnaire; health related quality of life assessed using euroqol EQ-5D-5L;&#xD;
      axillary recurrence free interval (ARFI); local recurrence; regional (nodal) recurrence;&#xD;
      distant metastasis; overall survival; contralateral breast cancer; non-breast malignancy;&#xD;
      costs; quality adjusted life years (QALYs) and cost-effectiveness.&#xD;
&#xD;
      Sample size: A sample size of 1900 patients would have the ability to demonstrate a 3.5%&#xD;
      non-inferiority margin with a 5% 1-sided significance level and 85% power, allowing for 7%&#xD;
      non-collection of primary outcome data assuming a 90% 5-year disease free survival rate in&#xD;
      the control arm. It would also be able to detect at least a 5% difference in proportion of&#xD;
      patients with lymphoedema with 90% power, a 5% 2-sided significance level and allowing for&#xD;
      25% non-collection of primary outcome data over 5 years.&#xD;
&#xD;
      Analysis plan: All analyses will be carried out on an intention-to-treat basis to preserve&#xD;
      randomisation, avoid bias from exclusions and preserve statistical power. Time to event&#xD;
      outcomes, including disease free survival and axillary recurrence free interval, will be&#xD;
      assessed using Kaplan-Meier curves and compared using Cox proportional hazards models. The&#xD;
      proportion of patients experiencing lymphoedema at 5 years will be compared across trial arms&#xD;
      using a chi-squared test and a logistic regression model used to adjust for stratification&#xD;
      variables. Arm morbidity and health related quality of life will be scored using the&#xD;
      appropriate manuals and assessed using a longitudinal mixed model regression analysis if&#xD;
      model assumptions valid or a standardised area-under-the-curve analysis. For economic&#xD;
      evaluation, incremental cost per QALY gained at 5 years will be estimated.&#xD;
&#xD;
      Timelines for delivery: Total project duration is 120 months based on 6 months for set up; 60&#xD;
      months recruitment period (including an 18 months internal pilot phase); and 54 months for&#xD;
      follow up, analysis, writing up and dissemination.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2030</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2030</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>5 years</time_frame>
    <description>DFS calculated as the time from randomisation until the date of first event of either a loco-regional invasive breast cancer relapse, distant relapse, ipsilateral or contralateral new invasive primary breast cancer or death by any cause or the censor date.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient reported lymphoedema</measure>
    <time_frame>5 years</time_frame>
    <description>Lymphoedema is self-reported based on two items from the validated Lymphoedema and Breast Cancer Questionnaire (arm &quot;swelling now&quot; and arm &quot;heaviness in the past year&quot;). Lymphoedema is defined as 'yes' to both questions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arm function</measure>
    <time_frame>5 years</time_frame>
    <description>Arm function will be assessed using shortened version of the Disability of the Arm, Shoulder and Hand (DASH), the 11-item QuickDASH questionnaire. Physical disability is defined as a change from baseline in the QuickDASH score of at least 14 points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life: EQ-5D-5L</measure>
    <time_frame>5 years</time_frame>
    <description>Health related quality of life will be assessed with EQ-5D-5L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Axillary recurrence free interval</measure>
    <time_frame>5 years</time_frame>
    <description>Axillary recurrence free interval, calculated from the date of randomisation to the date of axillary recurrence or the censor date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival calculated as the time from randomisation until the date of death by any cause or the censor date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local (breast or chest wall) recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>Number of participants with local (breast or chest wall) recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional (nodal) recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>Number of participants with regional (nodal) recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis</measure>
    <time_frame>5 years</time_frame>
    <description>Number of participants with distant metastasis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Contralateral breast cancer</measure>
    <time_frame>5 years</time_frame>
    <description>Number of participants with contralateral breast cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-breast cancer</measure>
    <time_frame>5 years</time_frame>
    <description>Number of participants with non-breast cancer</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1900</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Sentinel Lymph Node</condition>
  <condition>Neoplasm, Breast</condition>
  <arm_group>
    <arm_group_label>No axillary treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this arm will not receive axillary treatment (axillary lymph node dissection or axillary radiotherapy). Supraclavicular fossa radiotherapy is not allowed when randomised to this arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Axillary treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive axillary treatment. Axillary treatment can be axillary lymph node dissection or axillary radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Axillary lymph node dissection</intervention_name>
    <description>Participants will undergo removal of at least level I and II axillary lymph nodes.</description>
    <arm_group_label>Axillary treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Axillary radiotherapy</intervention_name>
    <description>Axillary radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.</description>
    <arm_group_label>Axillary treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Breast or chest wall radiotherapy</intervention_name>
    <description>Breast or chest wall radiotherapy will be delivered as per the Radiotherapy Trials Quality Assurance (RTTQA) guidelines.</description>
    <arm_group_label>Axillary treatment</arm_group_label>
    <arm_group_label>No axillary treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  T1-3N1M0 breast cancer at diagnosis (prior to NACT) by American Joint Committee on&#xD;
             Cancer (AJCC) staging 7th edition&#xD;
&#xD;
          -  Fine-needle aspiration (FNA) or core biopsy confirmed axillary nodal metastases at&#xD;
             presentation&#xD;
&#xD;
          -  Oestrogen receptor, progesterone receptor and HER2 status evaluated on primary tumour&#xD;
&#xD;
          -  Received standard NACT as per local guidelines&#xD;
&#xD;
          -  Ultrasound of the axilla at completion of NACT&#xD;
&#xD;
          -  Undergo dual tracer sentinel node biopsy after NACT and at least 3 nodes removed&#xD;
             (sentinel nodes and marked node). If axillary node sampling is performed following&#xD;
             failed localisation of sentinel nodes, patient will be eligible if at least 3 nodes&#xD;
             removed (including the marked node).&#xD;
&#xD;
          -  No nodal metastases post NACT (isolated tumour cells, micro or macrometastasis)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bilateral invasive breast cancer&#xD;
&#xD;
          -  Sentinel node biopsy prior to NACT&#xD;
&#xD;
          -  Marked node not removed except where the node/s removed show&#xD;
&#xD;
               -  evidence of downstaging with complete pathological response e.g. fibrosis or&#xD;
                  scarring&#xD;
&#xD;
          -  Previous axillary surgery on the same body side as the scheduled targeted sampling&#xD;
&#xD;
          -  Radiation therapy for the currently diagnosed breast cancer prior to randomisation&#xD;
&#xD;
          -  Previous cancer within 5 years or concomitant malignancy except&#xD;
&#xD;
               -  basal or squamous cell carcinoma of the skin&#xD;
&#xD;
               -  in situ carcinoma of the cervix&#xD;
&#xD;
               -  in situ melanoma&#xD;
&#xD;
               -  contra- or ipsilateral in situ breast cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit Goyal, MS, MD, FRCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Derby Hospital, Derby, UK</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amit Goyal, MS, MD, FRCS</last_name>
    <phone>+44 1332785538</phone>
    <email>amit.goyal@nhs.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>NHS Grampian</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatrix Elsberger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Benson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Countess of Chester Hospital NHS Trust</name>
      <address>
        <city>Chester</city>
        <zip>CH2 1HJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anita Hargreaves</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Derby and Burton</name>
      <address>
        <city>Derby</city>
        <zip>DE22 3NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emanuele Garreffa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NHS Lanarkshire</name>
      <address>
        <city>East Kilbride</city>
        <zip>G75 8RG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tareq Abdullah</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NHS Lothian</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Bedi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hull University Teaching Hospitals</name>
      <address>
        <city>Hull</city>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kartikae Grover</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NHS Forth Valley</name>
      <address>
        <city>Larbert</city>
        <zip>FK5 4WR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Subodh Seth</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leicester</name>
      <address>
        <city>Leicester</city>
        <zip>LE3 9QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Kaushik</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petros Charalampoudis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Free London</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debashis Ghosh</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden</name>
      <address>
        <city>London</city>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Krupa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bedfordshire Hospitals</name>
      <address>
        <city>Luton</city>
        <zip>LU4 0DZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth James</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NHS Borders</name>
      <address>
        <city>Melrose</city>
        <zip>TD6 9BS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Bedi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Tees Hospitals</name>
      <address>
        <city>Middlesbrough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brinda Sethugavalar</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Milton Keynes University Hospital NHS Trust</name>
      <address>
        <city>Milton Keynes</city>
        <zip>MK6 5LD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Taylor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Newcastle Upon Tyne Hospitals</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry Cain</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Helens and Knowsley Teaching Hospitals</name>
      <address>
        <city>Prescot</city>
        <zip>L35 5DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Kiernan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Hertfordshire Hospitals</name>
      <address>
        <city>St Albans</city>
        <zip>AL3 5PN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee Min Lai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Tees and Hartlepool Hospitals</name>
      <address>
        <city>Stockton-on-Tees</city>
        <zip>TS19 8PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matei Dordea</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Somerset NHS Trust</name>
      <address>
        <city>Taunton</city>
        <zip>TA1 5DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoe Goldthorpe</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospitals</name>
      <address>
        <city>Truro</city>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duncan Wheatley</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wrightington, Wigan and Leigh Teaching Hospitals</name>
      <address>
        <city>Wigan</city>
        <zip>WN1 2NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantinos Zacharioudakis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yeovil District Hospital NHS Trust</name>
      <address>
        <city>Yeovil</city>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Osborne</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://youtu.be/SFAzvkpkM84</url>
    <description>Training video for surgeons to remove the marked node during sentinel node biopsy</description>
  </link>
  <link>
    <url>https://youtu.be/Nq3tmI6l66s</url>
    <description>Training video for radiologists to mark the node using black dye tattoo</description>
  </link>
  <link>
    <url>https://youtu.be/nLA0fYihVOc</url>
    <description>Training video for radiologists to mark the node using clip</description>
  </link>
  <link>
    <url>https://www.youtube.com/watch?v=s5vqST08HYE</url>
    <description>ATNEC breast cancer study - Research Nurse and Patient Consultation</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 27, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals of Derby and Burton NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Dr Amit Goyal</investigator_full_name>
    <investigator_title>Consultant Oncoplastic Breast Surgeon &amp; Associate Professor</investigator_title>
  </responsible_party>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>sentinel node biopsy</keyword>
  <keyword>breast cancer</keyword>
  <keyword>tattooing node</keyword>
  <keyword>marking node</keyword>
  <keyword>clip node</keyword>
  <keyword>axillary ultrasound</keyword>
  <keyword>node positive</keyword>
  <keyword>axillary lymph node dissection</keyword>
  <keyword>axillary radiotherapy</keyword>
  <keyword>axillary treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

